Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386193525> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4386193525 endingPage "1193" @default.
- W4386193525 startingPage "1187" @default.
- W4386193525 abstract "Background: A cross sectional prospective observational study evaluated the trends and patterns of Adverse drug reactions of cisplatin in pulmonary cancer patients . Methods:Pulmonary cancer patients, who received cisplatin as chemotherapy regimen, were monitored for adverse reactions. New and old diagnosed cases of pulmonary cancer patients belonging to either gender and of all ages, who were receiving cisplatin under any standard regimen, were included for the study. Any ADR due to poisoning, over dosage were excluded from the study. The ADRs were recorded in Central Drugs Standard Control Organization forms. Casuality was assessed by the WHO Casuality Assessment Scale and Naranjos Alograthim. Results:A total number of 98 patients were reported during the study period, wherein a total number of 114 ADR cases were observed.The majority of patients were in the age group of 61-80 (n=45), followed by 41 -60 years (n=41, 41.83%) .Out of the total ADRs, most frequently reported one was vomiting 18 (15.78%) followed by anemia 16 (14.03%), nausea 13(11.40%) and hair loss 12 (10.52 %) which together constituted 51.73 % of the total ADRs. The other commonly encountered ADRs were diarrhea 8 (7.01%), thrombocytopenia 6 (5.26%), constipation 6 (5.26%) neutropenia 5(4.38) and neuropathy 5(4.38%).According to WHO-UMC scale, 37(37.75%) of reports to be certain,33(33.67%) of reports to be possible and 28(28.57%) of reports to be probable where there was no case recorded as unclassified or inaccessible.Naranjos scale which classified 65 (66.32%) to be probable and remaining 33 (33.67%) to be possible. Conclusion:Cisplatin has high potential for adverse effects. There is a need to improve the management of adverse effects. This study also emphasizes the need to improve pharmacovigilance awareness among physicians in order to improve the pharmacovigilance in India." @default.
- W4386193525 created "2023-08-27" @default.
- W4386193525 creator A5010218058 @default.
- W4386193525 creator A5035597658 @default.
- W4386193525 creator A5049057294 @default.
- W4386193525 creator A5051308141 @default.
- W4386193525 date "2023-07-31" @default.
- W4386193525 modified "2023-09-28" @default.
- W4386193525 title "ADVERSE DRUG REACTIONS (ADRS) OF CISPLATIN IN PULMONARY CANCER PATIENTS- ONE YEAR PROSPECTIVE STUDY" @default.
- W4386193525 doi "https://doi.org/10.21474/ijar01/17334" @default.
- W4386193525 hasPublicationYear "2023" @default.
- W4386193525 type Work @default.
- W4386193525 citedByCount "0" @default.
- W4386193525 crossrefType "journal-article" @default.
- W4386193525 hasAuthorship W4386193525A5010218058 @default.
- W4386193525 hasAuthorship W4386193525A5035597658 @default.
- W4386193525 hasAuthorship W4386193525A5049057294 @default.
- W4386193525 hasAuthorship W4386193525A5051308141 @default.
- W4386193525 hasBestOaLocation W43861935251 @default.
- W4386193525 hasConcept C121608353 @default.
- W4386193525 hasConcept C126322002 @default.
- W4386193525 hasConcept C197934379 @default.
- W4386193525 hasConcept C2776694085 @default.
- W4386193525 hasConcept C2777063308 @default.
- W4386193525 hasConcept C2780580376 @default.
- W4386193525 hasConcept C2780852908 @default.
- W4386193525 hasConcept C2781112942 @default.
- W4386193525 hasConcept C2781413609 @default.
- W4386193525 hasConcept C71924100 @default.
- W4386193525 hasConceptScore W4386193525C121608353 @default.
- W4386193525 hasConceptScore W4386193525C126322002 @default.
- W4386193525 hasConceptScore W4386193525C197934379 @default.
- W4386193525 hasConceptScore W4386193525C2776694085 @default.
- W4386193525 hasConceptScore W4386193525C2777063308 @default.
- W4386193525 hasConceptScore W4386193525C2780580376 @default.
- W4386193525 hasConceptScore W4386193525C2780852908 @default.
- W4386193525 hasConceptScore W4386193525C2781112942 @default.
- W4386193525 hasConceptScore W4386193525C2781413609 @default.
- W4386193525 hasConceptScore W4386193525C71924100 @default.
- W4386193525 hasIssue "07" @default.
- W4386193525 hasLocation W43861935251 @default.
- W4386193525 hasOpenAccess W4386193525 @default.
- W4386193525 hasPrimaryLocation W43861935251 @default.
- W4386193525 hasRelatedWork W1979130534 @default.
- W4386193525 hasRelatedWork W2081557631 @default.
- W4386193525 hasRelatedWork W2111792237 @default.
- W4386193525 hasRelatedWork W2259978766 @default.
- W4386193525 hasRelatedWork W2362108816 @default.
- W4386193525 hasRelatedWork W2375265431 @default.
- W4386193525 hasRelatedWork W2377198612 @default.
- W4386193525 hasRelatedWork W2389233550 @default.
- W4386193525 hasRelatedWork W2410473272 @default.
- W4386193525 hasRelatedWork W3003421087 @default.
- W4386193525 hasVolume "11" @default.
- W4386193525 isParatext "false" @default.
- W4386193525 isRetracted "false" @default.
- W4386193525 workType "article" @default.